

Attorney Docket No.: ALX-141

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicant : Yi Wang, Louis Matis and Scott Rollins  
Serial No.: 08/236,208  
Filed : May 2, 1994  
For : METHOD FOR THE TREATMENT OF GLOMERULONEPHRITIS

NOV 00 1994

GROUP 1800

Commissioner of Patents and Trademarks  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date below.

Date Mailed: October 26, 1994

October 26, 1994  
Date Signed

Chi Suk Kim  
Ms. Chi Suk Kim

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 CFR §1.56 and 37 CFR §1.97(b)(3), applicants wish to call the Examiner's attention to the references listed on the Modified 1449 Form submitted herewith. Copies of these references are enclosed.

References 2-3, 5-7, and 9-22 are discussed in applicants' specification.

Couser et al. (reference 4) discuss the association of complement with glomerulonephritis, with particular reference to the direct mediation of glomerular injury by the actions of the C5b-9 terminal complement components.

Floege et al. (reference 8) discuss the association of certain proteins with complement-dependent and complement-independent glomerular injury, and evaluates these proteins as markers of such types of injury. Experiments are reported that, *inter alia*, evaluate the effects of complement depletion by cobra venom factor (CVF) on certain types of glomerular injury.

In addition to the foregoing, applicants would also like to draw the Examiner's attention to the following copending application. By bringing this application to the Examiner's attention, applicant does not waive the confidentiality provisions of 35 U.S.C. §122.

U.S. Application Serial No. 08/217,391, entitled "Method for Reducing Immune and Hemostatic Dysfunctions During Extracorporeal Circulation" filed March 23, 1994 by inventors Scott Rollins, Brian R. Smith and Stephen P. Squinto.


A copy of this application is not being submitted herewith. However, if for any reason, the Examiner believes it is necessary or desirable for applicants to provide a copy of this application, the Examiner is requested to advise the undersigned, or applicant's attorney, Maurice M. Klee, Ph.D., 1951 Burr Street, Fairfield, CT 06430, (203) 255-1400, and a copy will be provided.

The Examiner is respectfully requested to initial a copy of the Modified 1449 Form and return it to applicants to indicate consideration of the references listed thereon in connection with the prosecution of this application.

Respectfully submitted,

Date:

10/26/94



Seth A. Fidel, Ph.D.  
Reg. No. P-38,449  
Alexion Pharmaceuticals  
25 Science Park, Suite 360  
New Haven, CT 06511  
(203) 776-1790



Attorney Docket No.: ALX-141

PATENT  
RECEIVED  
NOV 08 1994  
GROUP 1800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Yi Wang, Louis Matis and Scott Rollins  
Serial No.: 08/236,208  
Filed : May 2, 1994  
For : METHOD FOR THE TREATMENT OF GLOMERULONEPHRITIS

Commissioner of Patents and Trademarks  
Washington, D.C. 20231

MODIFIED 1449 FORM

---

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date below.

Date Mailed: October 26, 1994

October 26, 1994  
Date Signed

Ms. Chi Suk Kim  
Ms. Chi Suk Kim